The role of chemotherapy in the treatment of bone and soft tissue sarcomas

被引：2

作者：

Longhi, A ^{[1
]}

Setola, E ^{[1
]}

Versari, M ^{[1
]}

Bacci, G ^{[1
]}

机构：

[1] Ist Ortoped Rizzoli, Dept Musculoskeletal Oncol, I-40136 Bologna, Italy

来源：

CURRENT ORTHOPAEDICS | 2005年 / 19卷 / 02期

关键词：

sarcomas; bone; soft tissue; chemotherapy;

D O I：

10.1016/j.cuor.2005.02.009

中图分类号：

R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学（修复外科学）];

学科分类号：

摘要：

White surgery remains the cornerstone of treatment of bone and soft tissue sarcomas, chemotherapy has improved the 5-year overall survival in osteosarcoma and Ewing's sarcoma from 10% to 70% in localized disease. Patients with metastases at presentation treated with surgery combined with chemotherapy have a 3-year survival of 30-50%, but cure is stilt rare. The role of adjuvant chemotherapy in soft tissue sarcoma has yet to be determined, but it is likely that some patients will benefit. As some bone sarcomas do not respond to chemotherapy, surgery remains the only effective treatment, and there are no effective drugs to treat relapsing patients. Radiotherapy has both a curative role in combination with chemotherapy in soft tissue and Ewing's sarcoma and a palliative rote in the other sarcomas. (c) 2005 Elsevier Ltd. All rights reserved.

引用

页码：119 / 126

页数：8

共 35 条

[1]

*AM JOINT COMM CAN, 2002, CANC STAG MAN, P221

[2] AN INTERGROUP PHASE-III RANDOMIZED STUDY OF DOXORUBICIN AND DACARBAZINE WITH OR WITHOUT IFOSFAMIDE AND MESNA IN ADVANCED SOFT-TISSUE AND BONE SARCOMAS [J].

ANTMAN, K ;

CROWLEY, J ;

BALCERZAK, SP ;

RIVKIN, SE ;

WEISS, GR ;

ELIAS, A ;

NATALE, RB ;

COOPER, RM ;

BARLOGIE, B ;

TRUMP, DL ;

DOROSHOW, JH ;

AISNER, J ;

PUGH, RP ;

WEISS, RB ;

COOPER, BA ;

CLAMOND, GH ;

BAKER, LH .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (07) :1276-1285

[3]

Bacci G, 2004, ONCOL REP, V11, P111

[4] Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide [J].

Bacci, G ;

Briccoli, A ;

Rocca, M ;

Ferrari, S ;

Donati, D ;

Longhi, A ;

Bertoni, F ;

Bacchini, P ;

Giacomini, S ;

Forni, C ;

Manfrini, M ;

Galletti, S .

ANNALS OF ONCOLOGY, 2003, 14 (07) :1126-1134

[5] Methotrexate serum concentration and histological response to multiagent primary chemotherapy for osteosarcoma of the limbs [J].

Bacci, G ;

Ferrari, S ;

Picci, P ;

Zolezzi, C ;

Gherlinzoni, F ;

Iantorno, D ;

Cazzola, A .

JOURNAL OF CHEMOTHERAPY, 1996, 8 (06) :472-478

[6]

BACCI G, 1993, CANCER, V72, P3227, DOI 10.1002/1097-0142(19931201)72:11<3227::AID-CNCR2820721116>3.0.CO

[7]

2-C

[8] RANDOMIZED COMPARISON OF 3 ADRIAMYCIN REGIMENS FOR METASTATIC SOFT-TISSUE SARCOMAS [J].

BORDEN, EC ;

AMATO, DA ;

ROSENBAUM, C ;

ENTERLINE, HT ;

SHIRAKI, MJ ;

CREECH, RH ;

LERNER, HJ ;

CARBONE, PP .

JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (06) :840-850

[9]

BRENNAN MF, 2002, CANC PRINCIPLES PRAC, P1738

[10] Soft tissue sarcomas [J].

Cormier, JN ;

Pollock, RE .

CA-A CANCER JOURNAL FOR CLINICIANS, 2004, 54 (02) :94-109

← 1 2 3 4 →